Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation of Revenue [Line Items]
Net sales	$ 4,400.1	$ 2,588.2
Brands
Disaggregation of Revenue [Line Items]
Net sales	2,724.6	1,061.5
Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	328.9	253.3
Generics
Disaggregation of Revenue [Line Items]
Net sales	1,346.6	1,273.4
Lipitor
Disaggregation of Revenue [Line Items]
Net sales	464.6
Norvasc
Disaggregation of Revenue [Line Items]
Net sales	227.7
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	187.8
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	139.6
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	103.7
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	89.0
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	76.6
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	76.6
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	69.9
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	57.9
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	45.9
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	45.1
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	40.3
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	36.9
Developed Markets | Brands
Disaggregation of Revenue [Line Items]
Net sales	1,403.7	891.5
Developed Markets | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	312.0	241.6
Developed Markets | Generics
Disaggregation of Revenue [Line Items]
Net sales	855.9	853.3
Greater China | Brands
Disaggregation of Revenue [Line Items]
Net sales	590.9	14.7
Greater China | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	0.0	0.1
Greater China | Generics
Disaggregation of Revenue [Line Items]
Net sales	1.0	0.3
JANZ | Brands
Disaggregation of Revenue [Line Items]
Net sales	284.0	90.6
JANZ | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	8.9	8.4
JANZ | Generics
Disaggregation of Revenue [Line Items]
Net sales	189.0	144.2
Emerging Markets | Brands
Disaggregation of Revenue [Line Items]
Net sales	446.0	64.7
Emerging Markets | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	8.0	3.2
Emerging Markets | Generics
Disaggregation of Revenue [Line Items]
Net sales	300.7	275.6
Operating Segment | Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	2,571.6	1,986.4
Operating Segment | Greater China
Disaggregation of Revenue [Line Items]
Net sales	591.9	15.1
Operating Segment | JANZ
Disaggregation of Revenue [Line Items]
Net sales	481.9	243.2
Operating Segment | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	$ 754.7	$ 343.5